Chromatin insulators partition the genome into functional units to control gene expression, particularly in complex chromosomal regions. The CCCTC-binding factor (CTCF) is an insulator-binding protein that functions in transcriptional regulation and higher-order chromatin formation. Variable CTCF-binding sites have been identified to be cell type-specific partly due to differential DNA methylation. Here, we show that DNA methylation-independent removable CTCF insulator is responsible for retinoic acid (RA)-mediated higher-order chromatin remodeling in the human HOXA gene locus. Detailed chromatin analysis characterized multiple CTCF-enriched sites and RA-responsive enhancers at this locus. These regulatory elements and transcriptionally silent HOXA genes are closely positioned under basal conditions. Notably, upon RA signaling, the RAR/ RXR transcription factor induced loss of adjacent CTCF binding and changed the higher-order chromatin conformation of the overall locus. Targeted disruption of a CTCF site by genome editing with zinc finger nucleases and CRISPR/Cas9 system showed that the site is required for chromatin conformations that maintain the initial associations among insulators, enhancers and promoters. The results indicate that the initial chromatin conformation affects subsequent RA-induced HOXA gene activation. Our study uncovers that a removable insulator spatiotemporally switches higher-order chromatin and multiple gene activities via cooperation of CTCF and key transcription factors.
Introduction
Distal cis-regulatory elements such as enhancers and locus control regions (LCRs), are often involved in cell type-and developmental stage-specific gene expression (1, 2) . Previous studies have shown that higher-order chromatin dynamics facilitates interactions between distal cis-regulatory elements and their target gene promoters (3, 4) . In combination with DNA methylation and histone modification, this spatiotemporal epigenetic gene regulation is essential for various pathophysiological phenomena in mammals.
Chromatin insulators, also known as boundary elements, define functional domains that ensure precise enhancerpromoter interactions within domains (5) . The CCCTC-binding factor (CTCF) is one of the best characterized insulator-binding proteins in vertebrates, and is responsible for insulator activities (6) . CTCF has also been shown to be a multi-functional factor that controls gene expression and organization of chromatin structure, which is involved in various cell regulation (7, 8) . Our and other detailed studies have demonstrated that CTCFdependent long-range interactions contribute to correct gene regulation in complex chromosomal regions, indicating that CTCF-mediated higher-order chromatin remodeling occurs in cell type-and cell state-specific manners (9) (10) (11) (12) (13) . Genome-wide studies have shown that CTCF is enriched at several tens of thousands of sites on the human genome (14) , and many CTCFbinding sites are located at the boundaries of different histone modification domains (15) and topologically associating domains (16) . By comparison of genome-wide occupancy patterns of CTCF in 19 diverse human cell types, 64% of CTCF sites vary in at least one cell type (17) . Interestingly, 41% of the cell-typespecific CTCF-binding sites were linked to differential DNA methylation, and 36% of them were unmethylated in all cell types tested. However, DNA methylation-independent control of CTCF binding at the target sites remains unclear.
In mammals, there are four HOX gene clusters (HOXA, B, C and D), containing 9-11 genes on distinct chromosomes. These gene clusters are spatiotemporally regulated in developmental processes, and are responsible for anterior-posterior (A-P) patterning in the body (18) . The HOXA gene locus responds to retinoic acid (RA) signaling, and primarily functions in cell differentiation and body development (19) . CTCF-enriched sites are found within the HOXA gene cluster. Ferraiuolo et al. reported that several chromatin loops are formed in the transcriptionally silent HOXA locus, and transcriptional induction by RA treatment is associated with loss of chromatin contact and unfolding of the cluster (20) . Additionally, it has been shown that CTCF depletion causes loss of chromatin loop structure and aberrant RA-induced gene activation at the HOXA cluster (21) . However, the molecular mechanism of higher-order chromatin remodeling mediated by CTCF insulators and RA signaling is largely unknown. In the present study, we found that a removable CTCF insulator is responsible for RA-mediated higher-order chromatin remodeling and selective gene expression at the HOXA gene locus. Using chromatin immunoprecipitation (ChIP) microarray analysis, we identified a composite binding site of CTCF and the Retinoic acid receptor (RAR)/Retinoid X receptor (RXR) complex in the human HOXA locus. The RA-bound RAR/ RXR complex binds to the composite CTCF/RAR/RXR site and remove CTCF from the site, resulting in loss of insulator function. Our study highlights a novel mechanism, with a DNA methylation-independent removable CTCF insulator reprograming higher-order chromatin and multiple gene activities through cooperation with specific transcription factors.
Results
Characterization of CTCF-dependent insulators and retinoic acid-responsive enhancers in the human HOXA gene cluster CTCF-enriched sites in the human HOXA locus were investigated using ChIP-on-chip analysis combined with several genome-wide CTCF-binding profiles available in published databases ( Fig. 1A and Supplementary Material, Fig. S1A ) (22) . At least six CTCF-enriched sites (named HA1, HA2, HA3, HA4, HA5 and HA6) were identified in this locus. Using electrophoretic mobility shift assays (EMSAs), we confirmed that CTCF bound directly and specifically to these HA sequences (Supplementary Material, Fig. S1C and D) . We next performed luciferase reporter assays to determine if individual HA sequences have enhancerblocking activity (Fig. 1B and Supplementary Material, Fig. S1E ). As shown using pIHLE-F, the presence of each HA between the enhancer and promoter reduced luciferase activity to approximately 20-50% of control pIHLE. HA sequences in the opposite direction showed similar results (pIHLE-R), indicating that these sites have enhancer-blocking activity that is independent of sequence orientation. To exclude the possibility that the HA sites exhibit silencer-like activities, HA sequences were inserted downstream of the enhancer (pIHLEI). Although HA2 slightly decreased luciferase activity, the rest of the HA sites did not, suggesting the sites do not possess silencer-like functions.
To address the biological significance of CTCF enrichment at the HOXA locus, we used human embryonal carcinoma NT2/D1 cells, because they differentiate into neuronal cells with retinoic acid (RA) treatment (Supplementary Material, Fig. S1F ), which is accompanied by HOX gene induction (23) . Using quantitative RT-PCR (qRT-PCR), we confirmed the expression pattern of HOXA genes under RA treatment (Fig. 1C) . As previously reported (20,21), 3 0 HOXA genes (HOXA1 to HOXA5) were selectively induced by RA treatment. In contrast, 5 0 HOXA genes (HOXA6 to HOXA13) remained silent. This result suggests that RA-responsive enhancers are located within the 3' HOXA gene locus.
To identify RA-responsive enhancers, we performed ChIPon-chip analysis using anti-RARa antibodies in NT2/D1 cells treated with RA for 6 days (Fig. 1A) . Additionally, we examined publicly available ChIP-seq data for RXRa (Supplementary mate rial, Fig. S1A and B) (22) . We found four candidate sites present in the intergenic region of RA-induced 3 0 HOXA genes that had consensus sequences for RAR/RXR-binding, known as retinoicacid response elements (RAREs). We named them RE1, RE2, RE3 and RE4 (Fig. 1A, Supplementary Material, Fig. S1A ,B and G). To our knowledge, three RA-responsive enhancers have previously been reported, which are virtually identical to RE2, RE3 and RE4 in this study (24) (25) (26) . To confirm RARa-binding to RE sites, we performed ChIP-qPCR using anti-RARa antibodies (Fig. 1D) The function of individual CTCF-enriched HA sites at the HOXA locus may be different in the RA-treated condition. To test this hypothesis, we examined the effect of RA treatment on CTCF binding to each HA site. ChIP-qPCR was performed in RAtreated NT2/D1 cells ( Fig. 2A) . Unexpectedly, the amount of CTCF was significantly reduced at only the HA6 site after RA treatment (maximally on day 6), and did not change at the other HA sites. Because RAD21 (a cohesion protein) is a known cofactor of CTCF (27) (28) (29) , we next examined its enrichment at the HA sites (Fig. 2B ). ChIP-qPCR data showed RAD21 strongly bound to HA1, HA3, HA5 and HA6, while RAD21 enrichment was significantly decreased at HA6 after RA treatment (day 6). To further determine if RA treatment affects histone modification at HA sites, we performed ChIP-qPCR using antibodies against acetylated histone H3 (AcH3) and tri-methylated lysine 27 of histone H3 (H3K27me3) in untreated and RA-treated cells (Fig. 2C ). AcH3 enrichment was significantly increased at HA6 after RA treatment (day 6), in comparison with the other HA sites. Conversely, the H3K27me3 mark was greatly decreased at HA6. Additionally, we tested the DNA methylation status of the HA6 site in untreated and RA-treated cells using bisulfite sequencing (Fig. 2D) . Although CTCF is known to be CpG methylationsensitive (17, 30, 31) RARa enrichment of the control HOXA5 exon 2 site was normalized to 1. (E) RA-responsive enhancer activities of RE sequences. Luciferase reporter vectors (pGL3-promoter, PGL3-RE1, -RE2, -RE3 and -RE4) were transfected into NT2/D1 cells, which were then untreated (RA-) or treated with RA for 24 h (RAþ). Luciferase activity of the pGL3-promoter (RA-) was set at 1. Values are given as mean 6 SD of the results from more than three independent experiments. *P < 0.05, **P < 0.01. Fig. S3M ). Together, these results suggest that in the presence of RARa/RXRa, CTCF does not bind to HA6. To further determine if the insulator activity of HA6 is abolished by RA treatment, we performed luciferase reporter assays in NT2/D1 cells ( Fig. 3C ) using HA6S, which contains RE1 and HA6 but not RE2. The H19 differentially methylated region (DMR) insulator was used as a positive control (pIHLIE). The presence of HA6S between the enhancer and promoter reduced luciferase activity to approximately 40% of original pIHLE in untreated NT2/D1 cells (pIHLIE-HA6S), indicating that HA6S has enhancer blocking activity. With RA treatment, pIHLIE-HA6S luciferase activity was significantly increased, suggesting that RA signaling inhibits HA6 insulator activity. Furthermore, use of mutant RE1 that lacks RAR/RXRbinding equally showed enhancer-blocking effects in both untreated and RA-treated cells (pIHLIE-HA6Smut). These results suggest that RA-mediated RAR/RXR binding to RE1, followed by loss of CTCF at HA6, disrupts insulator activity of the HA6 site.
Targeted Disruption of the HA6 Insulator Impairs Higher-Order Chromatin Conformation
To determine if the CTCF-mediated HA6 insulator is responsible for higher-order chromatin and gene regulation at the HOXA locus, we performed targeted disruption of the CTCF-binding sequence at HA6 in NT2/D1 cells using zinc-finger nucleases (ZFNs) (Fig. 4A, Supplementary Material, Fig. S4A (C) Significant changes in histone modification at HA6. ChIP-qPCR using antibodies against acetylated histone H3 (AcH3) and tri-methylated lysine 27 of histone H3 (H3K27me3) was performed in cells that were untreated (RA-) or treated with RA for 6 days (D6). Values are given as mean 6 SD of the results from more than three independent experiments. *P < 0.05, **P < 0.01. Thus, by using HA6 as a reference, we have identified chromatin conformation changes in RA-treated cells. Using HA6-replaced cells, we performed 3C assays with allele-specific reference primers, including 3C-HA6 for the WT allele and PGK-P5 for the HA6-NEO allele ( Fig. 4C and D) . The interaction frequency of the HA6 site with 9 distinct DpnII fragments was assessed separately using these two alleles. HA6 interacted with the other HA sites and RE4 enhancer using the WT allele, but not with the HA6-NEO allele. These results suggest that the CTCF-mediated HA6 insulator is required for chromatin conformations that maintain the initial association between HA and RE sites.
Deletion of the HA6 Insulator Alters the Initial Associations Among Enhancers, Promoters and Insulators
Although the monoallelic HA6-replaced cells are useful for analyzing the allele-specific chromatin interactions of HA6, it is unable to detect the allele-specific chromatin interactions of other elements, such as RE4, in this cell line. Additionally, transcriptional activity of the PGK-neo cassette and the insertion of this larger fragment might affect the chromatin state. To investigate the effect of loss of HA6 on the RE4 enhancer, we generated biallelic HA6-deleted cells by the CRISPR/Cas9 genome editing system. We designed two guide RNAs (gRNAs) that target distinct sites close to the CTCF-binding sequence of HA6 (Fig. 5A and structs were generated using the H19 DMR insulator (as a control; pIHLIE), HA6S (lacking the RE2 enhancer from HA6, shown in Fig. 1B ; pIHLIE-HA6S), or HA6Smut (lacking the RAR/RXR binding from HA6S; pIHLIE-HA6Smut). These constructs were introduced into NT2/D1 cells that were untreated or treated with RA for 24 hr. Luciferase activities from pIHLE were normalized to 100. Values are given as mean 6 SD of the results from more than three independent experiments. **P < 0.01.
Supplementary Material, Fig. S5A ). We transfected the Cas9/ gRNA expression vectors and hygromycin resistance gene into NT2/D1 cells, followed by hygromycin selection. PCR-based genotyping identified two candidate clones showing biallelic deletion of HA6 (Fig. 5B) . We confirmed targeted HA6 disruption by DNA sequencing and loss of CTCF binding to HA6 by ChIP assay (Supplementary Material, Fig. S5B and C) . Additionally, loss of HA6 did not alter RARa binding to RE1 in RA-treated cells (Supplementary Material, Fig. S5D ). Using biallelic HA6-deleted cells (clone #2-8), we analyzed the interaction frequency of the RE4 enhancer element with 21 BglII fragments from the HOXA locus (Fig. 5C) . Interestingly, the interacting frequency of RE4 with the HA5/HOXA5 gene and the HA3/HOXA7 gene was significantly increased in HA6-deleted cells. Additionally, loss of HA6 slightly enhanced the interaction between RE4 and 5' HOXA genes. We also found the chromatin conformation change in another HA6-deleted cell line (clone #3-4), that is similar but somewhat different from clone #2-8 (Supplementary Material, Fig. S5F ). Interestingly, the increase of the interaction between RE4 and HOXA5 was a common finding in HA6-deleted cells and RA-treated original NT2/D1 cells (Fig. 5C , Supplementary Material, Fig. S5E and F) . These results suggest that the CTCFmediated HA6 insulator is involved in chromatin conformations that maintain the initial associations among enhancers, promoters and insulators. We next examined the HOXA gene expression in HA6-deleted NT2/D1 cells (Fig. 5D ). Biallelic HA6 disruption did not show aberrant induction of HOXA genes under basal condition. However, expression levels of RA-induced HOXA genes were evidently changed. Interestingly, HOXA5 to HOXA3 and HOXA1 tended to be more activated by RA treatment, whereas HOXA2 expression was slightly reduced on day 2 after RA treatment. Importantly, this aberrant RA-induced gene expression did not cause by change of H3K27me3 levels under basal condition (Supplementary Material, Fig. S5G ). It is noted that the RA-induced expression pattern of HOXA genes was different among HA6-targeted clones (Supplementary Materials, Fig. S4I and S5H ). This differential gene activity may due to distinct chromatin conformations of the HOXA locus (Supplementary Material, Fig. S5F ). This finding indicates that the initial chromatin conformation affects subsequent RAinduced gene expression.
RA-Treatment Forms Active and Inactive Chromatin Domains in the HOXA Locus
As shown, RA treatment induced 3 0 HOXA genes (HOXA1 to HOXA5) but not 5 0 HOXA genes (HOXA6 to HOXA13), suggesting that active and inactive chromatin domains have been formed at this locus. To clarify this, we performed ChIP-seq analysis using anti-AcH3 and anti-H3K27me3 antibodies (Fig. 6A) . Expectedly, the enrichment of AcH3 was hardly observed throughout this locus under basal condition and significantly increased within the 3' HOXA region (HOXA1 to HOXA5) in RAtreated cells. This is consistent with the HOXA gene expression pattern induced by RA treatment. In contrast, H3K27me3 covered the entire HOXA cluster under basal condition and was evidently decreased in the 5' HOXA region (HOXA1 to HOXA7) by RA treatment. These results were confirmed by ChIP-qPCR analysis (Supplementary Material, Fig. S6 ). Additionally, we found that RA treatment did not dramatically alter the active H3K4me3 mark (Supplementary Material, Fig. S6 ). Collectively, our results show that at least two chromatin boundaries (HA5 for H3 acetylation and HA3 for H3K27me3) are produced under RA treatment, and HA6 do not function as a chromatin boundary in this context.
Discussion
We have identified six CTCF-enriched sites (HA1-6) in the HOXA locus using ChIP-on-chip data and available databases. All of these sites exhibit enhancer-blocking activities in luciferase reporter assays. Importantly, we found that the enhancerblocking activity of HA6 is markedly reduced by RA treatment due to neighbouring RAR/RXR binding to RE1, suggesting that the insulator activity of HA6 is controlled by RA signaling (Fig. 6B) . Of great interest, RA treatment diminished CTCF at HA6 but not at the other sites. Our EMSA results suggest that the RAR/RXR complex competes with CTCF at adjacent binding sites. Additionally, a previous study revealed that RXRa physically interacts with CTCF (34), suggesting that the RAR/RXR complex interacts with CTCF and prevents it from binding to the HA6 site. To further examine the role of HA6 in HOXA cluster regulation, we generated HA6-targeted cells by genome editing. Our results show that HA6 disruption alters the interaction of the RE4 enhancer with the other insulators and HOXA gene promoters, and changed RA-induced gene expression, suggesting that HA6 primarily functions to maintain the stable repressive chromatin structure and fine-tune expression of nearby genes by ensuring proper enhancer-promoter interactions. Additionally, sequences including HA6 and RE1 are highly conserved in mouse, and HA6 shows cell-type-specific CTCF binding (Supplementary Material, Fig. S2 ), suggesting that these elements are crucial for the regulation of HOXA genes.
We observed that the RAR/RXR complex not only activates enhancers, but also changes the higher-order chromatin conformation by removing CTCF at the neighbouring insulator in the HOXA locus. Some studies have found that CTCF function is modulated by neighbouring transcription factors (35, 36) . Upon ligand binding, the thyroid hormone receptor (TR) reduces the insulator activity of CTCF in the chicken lysozyme and human c-myc gene loci, although this does not result from CTCF removal at the binding site (36) . Furthermore, Weth et al. reported that about 18% of CTCF sites in the human genome are close to potential TR binding sites, and that one of ten composite CTCF/ TR sites showed TR-sensitive insulator activity (34). Although we found that 6-10% of CTCF sites are overlapped with RAR/ RXR sites in cultured human cells and approximately 70% of CTCF sites in mouse tissues (Supplementary Material, Fig. S3C-K) , we did not check if all of the sites have both consensus sequences of CTCF and RAR/RXR. Therefore, it is likely that the overlapped sites include indirect DNA-protein interactions and that binding sites of these proteins are distant from each other, which may not be removable insulators. However, at least one site, located in the APOA1 locus, showed the decrease of CTCF binding by RA treatment (Supplementary Material, Fig. S3L ), suggesting that RA-regulated removable insulators may be present and function at some other loci.
A previous study characterized one of the CTCF-enriched sites in the HOXA locus (37) . The named CBS5 site, which is identical to HA3, is located between active and inactive HOXA genes, and possesses barrier activities in human lung fibroblast IMR90 cells and neural progenitor cells derived from mouse ES cells. Furthermore, a recent study showed the function of the C5j6 site, which is identical to HA5, in the mouse HoxA locus (38) . This site serves as a boundary for H3K4me3-and RNA polymerase II-enriched domain to prevent the expansion of active chromatin into the repressive chromatin domain in ES cellderived motor neurons. The other HA sites may also function as boundaries between different domains in a cell type-or developmental stage-specific manner.
Materials and Methods

Cell culture
The human embryonal carcinoma cell line NTERA-2 cl.D1 (NT2/ D1) and the human hepatoma cell line Hep3B were cultured in Dulbecco's modified Eagle's minimum essential medium (DMEM; Wako Pure Chemical Industries) supplemented with 10% (v/v) fetal bovine serum (FBS). For RA treatment, NT2/D1 cells were treated with 10 lM all-trans-retinoic acid (RA; Wako Pure Chemical Industries).
Chromatin immunoprecipitation (ChIP) microarray analysis
ChIP-on-chip analysis was essentially performed as described previously (10) . Briefly, ChIP-immunoprecipitated DNA and control DNA (whole-cell extract; WCE) were amplified by in vitro transcription, labelled with biotin, and hybridized to GeneChip ENCODE 2.0R arrays (Affymetrix). After scanning and data extraction, enrichment values (ChIP/WCE) were analyzed using Tiling Analysis Software (TAS; Affymetrix), and significantly enriched regions were visualized using the Integrated Genome Browser (IGB; Affymetrix), according to the manufacturer's instructions.
ChIP and qPCR analysis
ChIP was performed as described previously (39) , with some modifications. For ChIP with anti-RARa antibodies, NT2/D1 cells were treated with dimethyl 3,3 0 -dithiobispropionimidate-2HCl DNA enrichment in ChIP samples was determined by qPCR analysis using Thermal Cycler Dice Real Time System (Takara Bio) and SYBR green fluorescence. The threshold was set to cross the point of linear PCR amplification, and the cycle number required to reach the threshold recorded and analyzed using Microsoft Excel. PCR was performed using precipitated and input DNA. Primer sequences are listed in Supplementary Material, Table S1 .
Electrophoretic mobility shift assay (EMSA)
EMSA was performed using the DIG Gel Shift Kit 2 nd generation (Roche), according to the manufacturer's protocol. CTCF, RARa, and RXRa proteins were synthesized using coupled in vitro transcription/translation reactions with TNT T7 Quick for PCR (Promega), according to the manufacturer's protocol. For supershift assays, the reaction mixture was combined with 1 ll anti-CTCF (612149; BD Biosciences) or anti-RARa (sc-551X; Santa Cruz) antibodies.
DNA pull-down assay 
Luciferase reporter assay
The reporter vectors, pIHLE and pIHLIE, have been described previously (11) . To generate pIHLIE-F and pIHLIE-R plasmids, PCR-amplified fragments including HA1, HA2, HA3, HA4, HA5, and HA6 were inserted into pIHLE between the luciferase gene and the enhancer in the forward or reverse direction, respectively. For pIHLEI, HA fragments were inserted downstream of the enhancer in pIHLE. The HA6S fragment was prepared by truncating the HA6 fragment with PstI. To prepare the HA6Smut fragment, base substitutions were introduced to the RAR/RXR recognition sequence at the RE1 site using a PCR-based mutagenesis method. The reporter vectors, pGL3-RE1, -RE2, -RE-3 and RE4 were constructed by inserting RE1, RE2, RE3 and RE4 fragments (Supplementary Material, Fig. S1G ) downstream of the luciferase gene in the pGL3-Promoter vector (Promega). The primers used to prepare HA and RE fragments are listed in Supplementary Material, Table S1 . For enhancer-blocking assays, reporter vectors (0.2 pmol) and the CTCF expression vector (1 lg) were transfected into Hep3B cells (1.0 Â 10 5 cells) in 12-well plates using Xfect transfection reagent (Takara Bio), and then analyzed after 24 h using a Dual-Luciferase Reporter Assay system (Promega). For enhancer-blocking assays with RA treatment, NT2/D1 cells were transfected with reporter vectors (0.1 pmol) using Turbofect transfection reagent (Thermo Scientific), and incubated for 24 h in the presence or absence of RA (10 lM). Similarly, to assess enhancer activities of RE sites, reporter vectors were transfected into NT2/D1 cells and incubated for 24 hr. Values are shown as mean 6 standard deviation of the results from at least three independent experiments.
Chromosome conformation capture (3C) assay and qPCR analysis
For 3C assays, formaldehyde-crosslinked chromatin from NT2/ D1 cells was digested with BglII or DpnII overnight, followed by ligation with T4 DNA ligase at 16 C for 45 min. After reversing the crosslinks, genomic DNA was purified using the Wizard DNA clean-up system (Promega). To prepare control templates for standard curves, PAC (RP1-170O19) and BAC (CTD-2053N16) clones spanning the HOXA locus were digested with BglII, followed by random re-ligation. For control templates for the 3C assay with DpnII, equal molar amounts of PAC (RP1-170O19), BAC (CTD-2053N16) and the PGK-Neo cassette (GeneBridges) were digested with Sau3AI, which is insensitive to Dam methylase, followed by random re-ligation. The ligated product assessment was performed by qPCR with Thermal Cycler Dice Real Time System (Takara Bio) and SYBR green fluorescence. After the entire 3C treatment, restriction digest efficiency was evaluated using qPCR to amplify uncut fragments spanning restriction sites. Greater than 80% of individual restriction sites were digested (data not shown). 3C qPCR data were normalized to a loading control with internal primers located at HOXA10 and HOXA7 promoters. Relative interaction frequencies between the reference and its physically close site in the control state were normalized to 1. Statistical analysis was performed using Student's t-test from more than three independent experiments. Primer sequences are listed in Supplementary Material, Table S1 .
Genome editing
ZFNs were designed using the module assembly method (40) (41) (42) . The target sequences and recognition a-helices for each zinc finger were: Fig. S5B ). ZFN expression vectors, driven by the CMV promoter, and a targeting vector that consists of 1-kb arms, the PGK-neo cassette (GeneBridges), and a diphtheria toxin A (DT-A) cassette, were transfected into NT2/ D1 cells using TurboFect transfection regent (Thermo Scientific) and selected with G418 (500 lg/ml) for one week. For CRISPR/ Cas9 genome editing, two guide RNA (gRNA) were designed near to the HA6 site using CRISPRdirect. The annealed oligonucleotides (Supplementary Material, Table S1 ) were cloned into the BbsI site of the px330 vector (Addgene plasmid # 42230) (44) . The vectors were electroporated into NT2/D1 cells together with the pIRES-Hyg3-EGFP vector using GenePulser Xcell (BioRad). The pIRES-Hyg3-EGFP vector was generated by insertion of the NheI-BglII EGFP gene fragment (pEGFP-C1: Clontech) into the NheI-BamHI sites of the pIRES-Hyg3 vector (Clontech). The electroporated cells were selected with Hygromycin B (100 lg/ml) for 3 days and cultured for another 2-3 weeks without antibiotic selection. Genomic DNA was extracted from isolated colonies and genotyping was performed by PCR with specific primers (Supplementary Material, Table S1 ).
ChIP-seq analysis
ChIP was performed with ChIP-IT Express Enzymatic kit (Active motif) according to the manufacturer's instructions with some modifications. Briefly, cells were fixed with 1% formaldehyde for 10 min at room temperature. After enzymatic chromatin digestion, we performed sonication (5x30 sec) using the Bioruptor (Diagenode). Antibodies used were anti-acetylated histone H3 (06-599; Millipore) and anti-trimethylated H3K27 (07-449; Upstate). ChIP-seq libraries were constructed with NEBNext Ultra DNA Library Prep Kit for Illumina (NEB) and NEBNext Multiplex Oligos for Illumina (NEB) according to the manufacturer's instructions, and sequenced on the Illumina NextSeq 500 sequencer. Raw ChIP-seq data were processed with Galaxy (45) . Reads were mapped to the human genome (hg19) using Bowtie2. Significantly enriched regions were detected by SraTailor (46) . ChIP-seq data obtained from the Gene Expression Omnibus (GEO) database were re-analyzed by SraTailor. Peaks of ChIP-seq data were visualized using the Integrated Genome Browser (IGB). Overlap between each data sets were analyzed by BEDTools (47) .
Data Availability
ChIP-on-chip and ChIP-seq datasets have been deposited in the Gene Expression Omnibus (GEO) database under the accession number GSE80706.
Supplementary Material
Supplementary Material is available at HMG online.
